Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barlogie, B.
Right arrow Articles by Beck, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barlogie, B.
Right arrow Articles by Beck, T.

Stem Cells, Vol 11, 88-94, Copyright © 1993 by AlphaMed Press

REVIEWS

Recombinant human erythropoietin and the anemia of multiple myeloma

B Barlogie and T Beck
Division of Hematology-Oncology, University of Arkansas for Medical Sciences, Little Rock 72205.

The anemia of multiple myeloma (MM) is multifactorial, including physical replacement of normal hemopoiesis by tumor cells, renal failure and cytokines which contribute to the blunted erythropoietin (EPO) response observed in anemias of chronic disease. Recombinant EPO has been evaluated in anemic patients with stable multiple myeloma (< or = 10g% hemoglobin). Responses (> or = 2g% hemoglobin increase) were observed in 78% of 41 patients in two separate studies. Responses were associated with an increase in bone marrow erythropoietic cell compartment and reticulocytosis. Evaluation of potential parameters affecting response identified prolonged cytotoxic therapy for > 12 months, especially with alkylating agents and pre-treatment EPO levels > 100 U/L, both of which seemed to decrease the likelihood of EPO response. EPO is a safe and effective treatment for the anemia associated with MM.


This article has been cited by other articles:


Home page
 The OncologistHome page
T. J. Littlewood, M. Zagari, C. Pallister, and A. Perkins
Baseline and Early Treatment Factors are not Clinically Useful for Predicting Individual Response to Erythropoietin in Anemic Cancer Patients
Oncologist, February 1, 2003; 8(1): 99 - 107.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
Email Content Delivery
Copyright © 1993 by AlphaMed Press.